1. China Stocks

  2. •

    Retail trade

  3. •

    Drugstore chains
Landfar Bio-medicine Co., Ltd. Class A

Landfar Bio-medicine Co., Ltd. Class A

SSZSE:000504
8.97
CNY
-0.02
(-0.22%)
0.04EPS
83.92P/E
2.38BMarket Cap
Landfar Bio-medicine Co., Ltd. Class A
SZSE:000504
(Shenzhen Stock Exchange)

Recent

price

8.97

P/E

ratio

83.92

div

yld

0.08%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.47
0.3
0.25
0.08
0.06
0.04
0.22
0.22
0.3
0.43
0.65
0.49
0.64
0.44
0.41
1.3
1.99
Revenue per Share
0.02
-0.1
-0.48
0.04
-0.08
-0.07
0.07
-0.12
-0.11
0.06
0.03
-0.06
-0.04
-0.09
-0.06
0.09
0.09
Basic EPS, GAAP
-0.2
-0.01
-0.01
-0.1
-0.1
-0.1
-0.06
-0.16
-0.08
0.04
-0.78
0.24
0.48
0.1
-0.04
-0.38
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.01
0.01
0.03
0.03
0.04
- -
0.01
0.01
0.01
- -
0.01
0.01
Dividend per Share
0.5
0.41
-0.07
- -
0.02
-0.05
0.02
0.08
-0.03
0.06
0.09
0.05
0.04
0.78
0.72
0.81
0.82
Book Value per Share
-0.07
-0.17
-0.16
-0.07
-0.04
-0.1
-0.09
-0.02
-0.25
0.01
0.04
0.03
0.02
0.77
0.71
0.62
0.64
Tangible Book Value per Share
323
299
311
345
327
303
311
309
320
313
272
319
311
313
331
320
330
Basic Weighted Avg Shares
152
91
77
26
18
13
67
67
95
134
176
157
200
137
134
416
658
Sales/Revenue/Turnover
0.84
-9.72
7.44
-73.08
-95.49
-135.53
-9.03
-39.9
-13.7
-3.82
13.92
2.55
6.09
-6.62
-1.51
7.42
5.04
Operating Margin (%)
3
1
1
1
5
5
4
2
5
6
3
7
6
6
6
7
- -
Depreciation Expense
6
-30
-149
14
-26
-21
22
-37
-35
19
8
-19
-12
-28
-20
29
28
Net Income, GAAP
3.96
- -
- -
39.49
- -
- -
11.96
- -
- -
- -
22.84
- -
- -
- -
- -
8.47
- -
Effective Tax Rate (%)
4.25
-32.9
-194.27
52.52
-142.34
-158.65
32.35
-55.08
-36.89
14.02
4.64
-12.21
-6.22
-20.6
-14.76
6.93
4.31
Profit Margin (%)
-42
-70
-51
-67
-62
-75
-40
-14
-80
-6
59
-12
-39
202
96
194
198
Working Capital
1
1
1
1
1
1
1
20
1
1
19
17
15
13
19
56
55
LT Debt
161
130
-21
4
7
-15
80
128
108
114
134
110
80
305
282
358
359
Total Equity
3.99
- -
- -
- -
- -
- -
20.14
- -
- -
- -
8.55
- -
- -
- -
- -
3.98
- -
Return on Invested Capital (%)
4.53
- -
- -
-198.58
- -
- -
13.84
- -
- -
- -
2.85
- -
- -
- -
- -
8.25
- -
Return on Capital (%)
4.33
-21.18
- -
- -
-907.3
- -
- -
-248.16
- -
- -
36.26
-88.53
-81.29
-20.8
-8.03
11.47
11.18
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
285
292
162
LT Borrowings
53
53
53
LT Finance Leases
3
5
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
330
330
330
Market Capitalization
2,954
3,320
2,376

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
739
767
632
Cash, Cash Equivalents & STI
347
303
309
Accounts Receivable, Net
219
164
141
Inventories
19
49
54
Total Current Liabilities
545
555
435
Payables & Accruals
- -
- -
- -
ST Debt
285
292
162
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-32.72%
50.8%
26.78%
Free Cash Flow
-141.29%
107.32%
797.26%
Net Income, GAAP
-120.65%
-103.62%
-245.26%
Sales/Revenue/Turnover
70.92%
38.61%
209.37%
Total Cash Common Dividend
44.77%
44.67%
159.48%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
26
30
36
42
134
2025
22
29
- -
333
416
2026
119
177
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.02
- -
-0.03
-0.06
2025
-0.01
- -
- -
0.07
0.09
2026
0.03
-0.02
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
-0.01
- -
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Similar Companies
CVS Health Corporation (NYSE:CVS)
MatsukiyoCocokara & Co. (TSE:3088)
TSURUHA Holdings, Inc. (TSE:3391)
Guardian Pharmacy Services, Inc. (NYSE:GRDN)
MedPlus Health Services Ltd. (NSE:MEDPLUS)
Raia Drogasil S.A. (B3:RADL3)
Business
Landfar Bio-medicine Co., Ltd (000504.SZ) operates as a China-based biomedical technology company focused on cell therapy, regenerative medicine, and energy conservation; it provides stem cell storage and technical services, stem cell therapy research and development, medical device procurement and sales, biological resource storage, CNI Biomedicine Index business; and energy saving engineering, distributed energy station investments, comprehensive sewage treatment for special industries, build-transfer projects, and related product sales. Headquartered in Changsha, Hunan Province, the company was founded in 1991 as a restructuring of Hainan International Real Estate Development Co., Ltd. and listed on the Shenzhen Stock Exchange in December 1992; it primarily serves the Chinese market through its Biomedicine and Energy Saving and Environmental Protection segments. In recent developments, Landfar Bio-medicine completed the acquisition of an additional 29% stake in Hunan Nanhua Amspring Biotechnology Co., Ltd., enhancing its control over biotechnology operations; the company also revised its articles of association in April 2024 and announced changes to its board of directors and independent directors during the same period.